earnings
confidence high
sentiment positive
materiality 0.80
GeneDx Q4 revenue $121M, +27% YoY; exome/genome +32%; reaffirms FY2026 guidance $540-555M
GeneDx Holdings Corp.
2025-FY EPS reported
-$0.73
revenue$427,539,000
- Q4 revenue $121M (+27% YoY); exome/genome revenue $104M (+32%, or +42% ex one-time).
- Q4 exome/genome volume 27,761 (+34.3% YoY); adjusted gross margin 71%.
- FY2025 revenue $427.5M (+41%); adjusted net income $41.8M vs $9.4M prior year.
- Reaffirmed FY2026 revenue guidance $540-555M with 33-35% exome/genome volume growth.
- Cash $172.3M; Q4 operating cash flow $5.1M; issued 147,583 shares via ATM netting $21.1M.